

Supplementary Table 1. Summary of Subject Genotyping Information

Analysis Set/Derivation	subjects	Platform	Quality^a	IBD^b	Gender
Discovery EOMG Sweden	189	Illumina 370K	10	1	2
Discovery EOMG England	121	Illumina 370K	3	1	0
Discovery EOMG France	118	Illumina 370K	0	3	0
Discovery EOMG Norway	26	Illumina 370K	0	0	0
Total Discovery EOMG Cases	454				
Replication EOMG Swedish	10	Illumina 610K	0	0	0
Replication EOMG English	128	Illumina 610K	10	0	5
Replication EOMG German	26	Illumina 610K	0	0	1
Replication EOMG Netherlands	46	Illumina 610K	0	0	0
Replication EOMG Norway	76	Illumina 610K	1	4	5
Total Replication EOMG Cases	286				
Discovery Controls	subjects	Platform	Quality^a	IBD^b	Gender
Sweden	570	Illumina 550K	0	0	0
British 1958 Blood Bank	1355	Illumina 550K	19	13	0
New York Cancer Project	1834	Illumina 550K	10	10	4
Norway ^f	123	Illumina 550K	4	0	0
Childrens Hospital of Philadelphia	1453	Illumina 550K	23	47	0
NIH Laboratory of Neurogenetics	170	Illumina 550K	0	0	0
Total	5505				
Replication Sweden Controls ^g	678	Illumina 1Mb	4	2	0
WTCCC Controls	2737	Illumina 1Mb	19	58	0
Total	3415				

a. Less than 95% complete genotypes

b. Exclusion for relatedness based on identity by state analyses ($PI^{\wedge} > 0.15$ assessed using PLINK IBD)

c. >10% nonEuropean admixture (see Supplementary Methods)

d. Based on PCA analyses (see Supplementary Methods)

e. Final set after exclusion or after best 4:1 match for controls (see Supplementary Methods).

f. Samples collected in Norway and genotyped in current study at North Shore.

g. Samples collected and genotyped in Sweden for population controls in myocardial infarction study.

non-European ^c	4 SD PCA ^d	Final Set ^e
9	5	162
3	1	113
16	0	99
0	0	26
		400
0	0	10
2	4	107
0	0	25
2	1	43
0	2	64
		249

non-European ^c	4 SD PCA ^d	4:1 match cases ^e
5	5	535
18	15	292
115	20	310
0	4	98
169	10	305
16	5	60
		1600
6	23	309
38	13	687
		996

).